Journal of Drugs in Dermatology最新文献

Background: Onychoschizia is characterized by distal nail plate splitting. Several therapeutic approaches exist, most of which are based on case reports or small non-comparative case series.

Objective: To evaluate safety and efficacy of oral biotin and pyridoxine for treating onychoschizia.

Patients and methods: A retrospective comparative study was conducted among patients with idiopathic fingernail onychoschizia. Patients were prescribed 1 mg/day biotin, or 100 mg/day pyridoxine or both, for 3 months. Complete response (improvement of more than 90%) and partial response (improvement of more than 50%) were assessed after 6 to 9 months.

Results: The study included 61 patients with fingernail onychoschizia (mean age 40.5 years [range 20-68 years]). The average number of affected fingernails was 7.0 (±2.0) per patient. The nail condition lasted 11.6 (±4.7) years on average. The combined treatment regimen achieved significantly higher rates of complete response compared to biotin or pyridoxine alone (69.6% vs 10%, 11.1%, respectively; P values < .001). Partial response (>50% improvement) was achieved in an additional 30.4%, 45%, and 38.9% of patients treated with combined regimen vs biotin or pyridoxine alone, respectively. No adverse events were recorded.

Conclusions: This study demonstrates that the use of biotin and pyridoxine combination is an effective treatment for fingernail onychoschizia. J Drugs Dermatol. 2025;24(2):174-177. doi:10.36849/JDD.7687R1.

Background: Laser resurfacing is one of the most popular aesthetic procedures that address a wide range of skin conditions and overall skin rejuvenation. To reduce downtime and improve the clinical efficacy of the procedures, it is important to design post-procedure care routines to complement them. Towards fulfilling that consumer need, a peptide synthesized from multi-component reaction (MCP) has been developed.

Aims:  The objective of this study is to investigate the functionalities of MCP as a regenerative active that enhances the healing kinetics and anti-aging performance following non-ablative fractional laser resurfacing procedures.

Methods:  To fulfill the objective, a single-center, split-face design, double-blinded, randomized clinical study was conducted. Study participants received a full face non-ablative fractional laser procedure followed by treatment with two topical products, MCP formula or Aquaphor Healing Ointment®or AHO (Beiersdorf Inc, Wilton, CT) as a standard of care topical agent. Both products were applied immediately after the laser procedure and continued two times daily for 28 days. Clinical evaluation and expert grading of healing and aging, instrument measurement of skin barrier function, optical coherence tomography and standardized digital imaging were performed.

Results:  Clinical evaluation results showed that the MCP formula promoted post-procedure skin healing at a comparable level as Aquaphor Healing Ointment®. However, the MCP formula demonstrated faster kinetics and enhanced level of improvement in multiple anti-aging parameters when compared with the benchmark control. Results from this clinical study demonstrate that the use of MCP formula post non-ablative fractional laser treatment is efficacious in promoting skin healing and enhancing the anti-aging benefits provided by the procedure. J Drugs Dermatol. 2025;24(2):188-195. doi:10.36849/JDD.8066R1.

The association between vitiligo and melanoma is complex. While the incidence of vitiligo in patients with melanoma is higher, the risk for the reverse, ie, the development of melanoma in a patient with vitiligo, is thought to be decreased. This report presents a case of melanoma developing on a non-sun-exposed site in a patient with skin of color and untreated vitiligo. It emphasizes the need to think critically about vitiligo and melanoma pathogenesis. J Drugs Dermatol. 2025;24(2):205-206. doi:10.36849/JDD.8115.

Background:  Dermatochalasis is characterized by the presence of redundant and loose upper eyelid skin, which occurs as part of the aging process and is often considered aesthetically undesirable. Currently, the gold standard for treatment is surgical blepharoplasty; however, non-surgical solutions are frequently requested. This study investigates the safety and efficacy of microplasma as a non-surgical method for treating dermatochalasis.

Methods:  Pre-clinic investigations were performed in vivo on porcine skin. Three pigs were treated with an increasing energy exposure of microplasma and biopsy samples were analyzed via histology. Subsequently, in a prospective clinical trial, 13 subjects with dermatochalasis were treated with MicroPlasma applicator. The subjects received 1 to 2 treatments with a treatment interval of 4 to 16 weeks. Results were assessed by blinded evaluation of pre- and post-treatment pictures and a patient questionnaire.

Results:  The in vivo porcine study showed skin ablation and dermal coagulation consistent with increasing plasma energy delivery, and subsequent healing process as expected, with neovascularization and fibroblast proliferation. In the clinical patient trial, blinded evaluations revealed improvement in the Dermatochalasis Scale (P<0.01) and improvement in the Global Aesthetics Improvement Scale. There were no serious adverse events.

Conclusion:  Microplasma is a successful non-surgical treatment option to reduce redundant skin of the upper eyelid with minimal adverse effects. J Drugs Dermatol. 2025;24(2):134-141. doi:10.36849/JDD.8635.

The use of alpha-hydroxy acids (AHAs) and beta-hydroxy acids (BHAs) for acne treatment and their integration into daily skincare routines for better cosmetic outcomes has increasingly become a norm, particularly in light of steep insurance deductibles and restricted access to prescription options. This article presents an analysis from a single-center, open-label study with 20 participants conducted to evaluate if an over-the-counter (OTC) barrier-restoring cream gel can alleviate the adverse skin reactions caused by a conventional dermatologist-recommended acne treatment plan in individuals with mild to moderate acne over 6 weeks. This evaluation encompassed both objective clinical assessments of facial skin health and subjective reports of product tolerability, complemented by before-and-after images and questionnaires to capture consumer feedback on the OTC moisturizer as well as an OTC salicylic acid-containing cleanser and spot treatment. J Drugs Dermatol. 2025;24(2):162-166. doi:10.36849/JDD.8502T1.

Dandruff and seborrheic dermatitis are associated with a disrupted scalp barrier that contributes to irritation, pruritus, and flaking of the scalp. The flaking and itch associated with dandruff can significantly impact an individual's self-esteem and quality of life. While the exact pathogenesis of dandruff is still not completely understood, scalp barrier health and its microbiome are thought to play significant roles in disease propagation. Five expert dermatologists with extensive experience in hair, dandruff, and seborrheic dermatitis were selected to participate in discussions that would result in five consensus statements focused on scalp barrier health and dandruff. Results of a systematic literature search and expert panel discussion are presented. These consensus statements aim to reflect expert opinions on the current understanding of scalp health in the context of dandruff and seborrheic dermatitis. The panel addressed challenges to promote scalp health, improve patient comfort, and prevent flares during dandruff management and maintenance. The presented consensus statements urge reframing our current understanding of dandruff and seborrheic dermatitis treatment by refocusing attention on global scalp and hair health. J Drugs Dermatol. 2025;24:2(Suppl 1):s8-14.

Ruxolitinib 1.5% cream is the first-in-class topical Janus kinase (JAK) inhibitor approved for the treatment of atopic dermatitis in patients 12 years of age and older. The US Food and Drug Administration (FDA) issued a "boxed warning" for ruxolitinib cream, cautioning about increased risks of serious infections, malignancies, blood clots, and cardiovascular events because it is a JAK inhibitor. Despite clinical trials and real-world data demonstrating the safety of ruxolitinib cream, the boxed warning remains in place, even though oral ruxolitinib - known for its significantly higher bioavailability and plasma concentration—has not been assigned this warning. As a result, this warning has caused hesitation in its use and has been a barrier to the broader, appropriate adoption of ruxolitinib cream despite its strong recommendation for use in atopic dermatitis (AD) by the American Academy of Dermatology in 2023. Here, we provide an in-depth overview of in vivo and ex vivo pharmacokinetic (PK) data from studies in minipigs and human cadaver skin, along with human PK data from pediatric and adult atopic dermatitis (AD) patients aged 2 years and older, as well as safety data from both clinical trials and real-world studies in AD patients. Together, this data reinforces the safety of topical ruxolitinib and reassures clinicians that they can utilize this medication in everyday practice. J Drugs Dermatol. 2025;24:2(Suppl 2):s16-22.

Hypertrophic scars and keloids represent abnormal wound healing, manifesting as raised scars confined to or extending beyond the wound margin, respectively. Understanding the risk factors associated with these scarring types is crucial for prevention and management. Utilizing the TriNetX global health research network database, we analyzed the data of 6,249 patients with hypertrophic scars or keloids. We employed the ICD-10 code L91.0 for identification, generating a control cohort matched by age, sex, and race. Associations between scarring and race, ethnicity, and various comorbidities were quantified. The analysis revealed that hypertrophic scars and keloids were more commonly associated with Black/African American individuals (OR=1.74, P<0.01) and less so with White races and Hispanic ethnicity. Significant comorbidities associated with increased risk included scarring alopecia, rosacea, atopic dermatitis, and acne. Inadequate sample size limited analysis for conditions like vitiligo. The findings suggest a higher prevalence of these scars in Black/African American races, potentially linked to melanocyte-mediated fibroblast and extracellular matrix activities. A notable correlation with inflammatory conditions suggests shared cytokine pathways, highlighting IL-4 and IL-13 as therapeutic targets. The strong association between scarring alopecia and skin cancers may implicate chronic inflammation and treatment-related scarring. Limitations of the study include its retrospective design, possible misdiagnosis, and small sample sizes for certain comorbidities. J Drugs Dermatol. 2025;24(2):212-215. doi:10.36849/JDD.8401R1.

Keloidal morphea is a rare variant of cutaneous scleroderma that presents with keloid-like plaques and nodules that occur most commonly on the neck, trunk, and proximal extremities. They occur in the absence of trauma or injury. Keloidal morphea most often manifests in patients with skin of color and may be mistaken for keloids and/or hypertrophic scars. This report presents a case of keloidal morphea in a young Black female. While effective therapies are limited, timely diagnosis can initiate the evaluation for systemic sclerosis and other systemic organ involvement. Increased awareness and recognition of keloidal morphea can help prevent dermatologic health disparities, which disproportionately occur in patients of color. J Drugs Dermatol. 2025;24(2):203-204. doi:10.36849/JDD.7960.